Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group

References

• Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: SEER, 2007. Available from: http://seer.cancer.gov/csr/1975_2004/. Accessed 2 April 2007.
   Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 2015; 385: 1873–1883.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101–1110.
   PubMed Web of Science ®Google Scholar
• Leblond V, Laribi K, Ilhan O, et al. Rituximab in combination with Bendamustine or Chlorambucil for treating patients with chronic lymphocytic leukemia: interim results of a Phase IIIb Study (MaBLe). Blood 2012; 120: 2744.
   Google Scholar
• Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007; 109: 2291–2298.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114: 3382–3391.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4378–4384.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014; 15: 48–58.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997–1007.
   PubMed Web of Science ®Google Scholar
• Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology Consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014; 32: 2595–2603.
   PubMed Web of Science ®Google Scholar
• Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy – a systematic review. Leuk Res 2014; 38: 275–283.
   PubMed Web of Science ®Google Scholar
• Ramjaun A, Nassif MO, Krotneva S, et al. Improved targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment. J Geriatr Oncol 2013; 4: 271–281.
   PubMed Web of Science ®Google Scholar
• Puts MT, Hardt J, Monette J, et al. Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst 2012; 104: 1133–1163.
   PubMed Web of Science ®Google Scholar
• Hamaker ME, Vos AG, Smorenburg CH, et al. The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer. Oncologist 2012; 17: 1439–1449.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
   PubMed Web of Science ®Google Scholar
• Parmelee PA, Thuras PD, Katz IR, et al. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995; 43: 130–137.
   PubMed Web of Science ®Google Scholar
• Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39: 142–148.
   PubMed Web of Science ®Google Scholar
• Kalbe E, Kessler J, Calabrese P, et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 2004; 19: 136–143.
   PubMed Web of Science ®Google Scholar
• Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179–186.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164–1174.
   PubMed Web of Science ®Google Scholar
• Goede V, Cramer P, Busch R, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: trial results of the German CLL Study Group. Haematologica 2014; 99: 1095–1100.
   PubMed Web of Science ®Google Scholar
• Reyes C, Satram-Hoang S, Hoang K, et al. What is the impact of comorbidity burden on treatment patterns and outcomes in elderly chronic lymphocytic leukemia patients? Blood 2012; 120: 758.
   Google Scholar
• Baumann T, Delgado J, Santacruz R, et al. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. Haematologica 2014; 99: 1599–1604.
   PubMed Web of Science ®Google Scholar
• Goede V, Raymonde B, Stilgenbauer S, et al. Cumulative Illness Rating Scale (CIRS) is a valuable tool to assess and weigh comorbidity in patients with chronic lymphocytic leukemia: Results from the CLL8 trial of the German CLL Study Group. Haematologica 2012; 97: 0154.
   Google Scholar
• Mulligan SP, Gill D, Turner P, et al. Toxicity is not associated with age or comorbidity score in a randomised study of oral fludarabine and cyclophosphamide and IV Rituximab (FCR) as first-line therapy of fit, elderly patients with Chronic Lymphocytic Leukemia (CLL). Blood 2014; 124: 4695.
   Google Scholar
• Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 2008; 56: 1926–1931.
   PubMed Web of Science ®Google Scholar
• Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012; 118: 3377–3386.
   PubMed Web of Science ®Google Scholar
• Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29: 3457–3465.
   PubMed Web of Science ®Google Scholar
• Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol 2015; 26: 288–300.
   PubMed Web of Science ®Google Scholar